SNN - Smith & Nephew plc
39.06 +0.25 (0.64%)
After hours: 4:03PM EDT
| Previous close | 39.44 |
| Open | 39.30 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 38.63 - 39.37 |
| 52-week range | 32.83 - 40.43 |
| Volume | 769,772 |
| Avg. volume | 873,304 |
| Market cap | 16.741B |
| Beta | 0.34 |
| PE ratio (TTM) | 22.12 |
| EPS (TTM) | 1.75 |
| Earnings date | N/A |
| Forward dividend & yield | 0.70 (1.83%) |
| Ex-dividend date | N/A |
| 1y target est | 42.90 |
- The Wall Street Journal•8 days ago
[$$] WPP Chairman Looks to Fill the Gap Left by Sorrell’s Sudden Exit
A little known private-equity executive will steer WPP PLC through one of its stormiest periods following the resignation last weekend of Martin Sorrell.
- Reuters•21 days ago
Smith & Nephew picks new CEO who sold his last company
Artificial hip and knee maker Smith & Nephew (SN.L), a perennial target of takeover speculation, said on Wednesday it had appointed a new chief executive with a track record of deal-making. Namal Nawana, who will replace Olivier Bohuon as CEO of the British company next month, most recently headed medical diagnostics firm Alere, where he oversaw its $5.3 billion sale to Abbott (ABT.N) in 2017. The medical technology firm, which also has wound-care and sports medicine units, is under pressure to improve margins and find new sources of growth as it competes with bigger rivals.
- Reuters - UK Focus•21 days ago
Smith & Nephew picks new CEO who sold his last company
Artificial hip and knee maker Smith & Nephew (Frankfurt: 502816 - news) , a perennial target of takeover speculation, said on Wednesday it had appointed a new chief executive with a track record of deal-making. Namal Nawana, who will replace Olivier Bohuon as CEO of the British company next month, most recently headed medical diagnostics firm Alere (NYSE: ALR - news) , where he oversaw its $5.3 billion sale to Abbott in 2017.
- Reuters - UK Focus•21 days ago
Smith & Nephew names Namal Nawana new CEO
Artificial hip and knee maker Smith & Nephew said on Wednesday it had appointed Namal Nawana to replace Olivier Bohuon as chief executive of the British company next month. Nawana was most recently chief ...
Sky News•21 days agoMedical devices maker S&N to name Nawana as new chief
The FTSE-100 medical devices group Smith & Nephew (Frankfurt: 502816 - news) (S&N) will this week end its six-month search for a new boss by naming a former Alere (NYSE: ALR - news) executive to the role. Sky News has learnt that S&N will announce on Wednesday that Namal Nawana will join the global leader in orthopaedics reconstruction in the coming months. Mr Nawana, a 46-year-old Australian citizen, will replace Olivier Bohuon, who told the medical technology group's board last October that he intended to step down this year.
- Zacks•27 days ago
Smith & Nephew (SNN): Moving Average Crossover Alert
Smith & Nephew plc (SNN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
- Market Realist•2 months ago
Johnson & Johnson’s Acclarent Aera Balloon Dilation System
Acclarent received FDA approval for its Acclarent Aera Balloon Dilation System for the treatment of ETD (eustachian tube dysfunction) in September 2016. For details, read Inside Johnson & Johnson’s Latest US Medical Device Launch. On February 27, 2018, Johnson & Johnson’s subsidiary Acclarent announced that the company received FDA approval for the expanded indication for Acclarent Aera.
- Zacks•2 months ago
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
Market Realist•2 months agoHow JNJ’s Orthopedic Medical Devices Performed in 4Q17 and 2017
How Johnson & Johnson's Medical Devices Business Fared in 2017
- Business Wire•2 months ago
Smith & Nephew: RCT demonstrates a 71% reduction in the onset of sacral pressure ulcers when adding ALLEVYN◊ LIFE to standard preventative protocol
LONDON--(BUSINESSWIRE)-- Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces the publication of a randomised controlled trial (RCT) demonstrating that the addition ...
- Business Wire•2 months ago
Smith & Nephew: RCT demonstrates a 71% reduction in the onset of sacral pressure ulcers when adding ALLEVYN◊ LIFE to standard preventative protocol
Smith & Nephew plc , the global medical technology business, today announces the publication of a randomised controlled trial demonstrating that the addition of ALLEVYN LIFE, Smith & Nephew’s leading multi-layer silicone adhesive foam dressing, to a standard care protocol significantly reduces the onset of pressure ulcers by 71% in elderly patients admitted to hospital for hip fracture1.
- Reuters - UK Focus•2 months ago
Smith & Nephew meets lower end of guidance range for 2017
Artificial hip and knee maker Smith & Nephew scraped into the bottom of its guidance range for 2017, with a 3 percent rise in revenue to $4.77 billion pounds and a 20 basis point increase in its trading ...
- Reuters - UK Focus•3 months ago
Britain's FTSE dips as pound gain weighs on exporters
The UK's top share index fell for a third straight day as a deepening global sell-off in the dollar strengthened sterling and dented earnings prospects for British companies exposed to the U.S. currency. ...
- Zacks•4 months ago
Smith & Nephew's Rotation Medical Deal Aids Tissue Regen Arm
Smith & Nephew's (SNN) completion of Rotation Medical acquisition appears highly strategic as this will consolidate the company's position in disruptive technologies and advance its overall growth.
Business Wire•4 months agoSmith & Nephew Announce European Launch of Handheld Imaging Technology Heralding a New Era of Evidence-Based Decision Making in Wound Care
LONDON--(BUSINESSWIRE)-- Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the European launch of MolecuLight i :X TM , the easy to use, handheld imaging device ...
- Business Wire•4 months ago
Smith & Nephew Announce European Launch of Handheld Imaging Technology Heralding a New Era of Evidence-Based Decision Making in Wound Care
Smith & Nephew , the global medical technology business, today announces the European launch of MolecuLight i:XTM, the easy to use, handheld imaging device
- Zacks•5 months ago
Will a 'Huge Tax Cut' Ease Burden for MedTech Players?
How is the MedTech industry placed in the wake of the current political conundrum surrounding tax reforms?
- Investor's Business Daily•5 months ago
Stocks Generating Improved Relative Strength: Smith & Nephew
Smith & Nephew shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
- Investor's Business Daily•6 months ago
Smith & Nephew Shows Rising Relative Price Performance; Still Shy Of Key Threshold
Smith & Nephew shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
- Reuters•6 months ago
Under pressure Smith & Nephew to focus on efficiency
Smith & Nephew (SN.L) said no major surgery is required for the artificial knee and hip maker to deliver shareholder value, even as it reported lacklustre sales that increase pressure on the company reportedly being stalked by activist investor Elliott. Two reports last month said that Paul Singer's U.S. hedge fund had taken a stake in Smith & Nephew, reigniting perennial speculation that it could be acquired by a U.S. rival such as Stryker (SYK.N) or be broken up.
- Reuters - UK Focus•6 months ago
Under pressure Smith & Nephew to focus on efficiency
Smith & Nephew (Frankfurt: 502816 - news) said no major surgery is required for the artificial knee and hip maker to deliver shareholder value, even as it reported lacklustre sales that increase pressure on the company reportedly being stalked by activist investor Elliott. Two reports last month said that Paul Singer's U.S. hedge fund had taken a stake in Smith & Nephew, reigniting perennial speculation that it could be acquired by a U.S. rival such as Stryker (Swiss: SYK.SW - news) or be broken up.
- Reuters - UK Focus•6 months ago
BUZZ-Smith & Nephew: weak FY rev outlook
** Smith & Nephew falls as much as 3.5% in decent volume before erasing losses ** Says revenue growth for FY will be at lower end of its 3-4 pct guidance ** Revenue $1.15 bln for the quarter, up 3 pct. ...
- Zacks•6 months ago
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
- Reuters•6 months ago
Smith & Nephew to buy Rotation Medical for up to $210 million
Medical technology group Smith & Nephew (SN.L), which some investors believe should streamline operations to make itself a more attractive takeover target, said on Monday it was buying a U.S. sports injury business for up to $210 million (£159 million). The British company, best known for its replacement hips and knees, will pay an initial $125 million to acquire unlisted Minnesota-based Rotation Medical, plus up to $85 million over the next five years if certain financial targets are hit.
